Analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to post earnings of ($0.09) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Viking Therapeutics’ earnings, with estimates ranging from ($0.12) to ($0.07). Viking Therapeutics posted earnings of ($0.10) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 10%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, May 8th.
According to Zacks, analysts expect that Viking Therapeutics will report full year earnings of ($0.47) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.34). For the next financial year, analysts anticipate that the company will post earnings of ($0.62) per share, with EPS estimates ranging from ($0.92) to ($0.43). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, March 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03.
VKTX traded up $1.43 during midday trading on Monday, hitting $9.94. The stock had a trading volume of 14,925,923 shares, compared to its average volume of 3,298,008. Viking Therapeutics has a 1 year low of $3.69 and a 1 year high of $24.00.
Large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Viking Therapeutics in the fourth quarter worth about $30,000. Lindbrook Capital LLC purchased a new position in Viking Therapeutics in the fourth quarter worth about $36,000. Quantbot Technologies LP purchased a new position in Viking Therapeutics in the third quarter worth about $109,000. Great West Life Assurance Co. Can purchased a new position in Viking Therapeutics in the fourth quarter worth about $53,000. Finally, Meeder Asset Management Inc. boosted its position in Viking Therapeutics by 63.5% in the fourth quarter. Meeder Asset Management Inc. now owns 7,309 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 2,839 shares during the last quarter. 65.31% of the stock is currently owned by institutional investors and hedge funds.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Read More: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.